IceCure Medical Enrolls First Patients in FDA-Approved ChoICE Study
IceCure Medical has officially begun patient enrollment for its post-market clinical study of the ProSense cryoablation system for breast cancer at two U.S. sites.
Stocks · News reference
IceCure Medical Completes First Patient Treatment in ChoICE Post-Marketing Study
IceCure Medical has successfully treated the first patient in its ChoICE post-marketing study, which evaluates the ProSense cryoablation system for treating low-risk breast cancer.
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- fiscal.ai
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
IceCure Medical Announces First Two Patients Enrolled In 400-Patient U.S. Post-Marketing Study Of ProSense Breast Cancer Cryoablation
IceCure Medical Announces Presentations, Posters And Physician Workshops On Its ProSense Breast Cancer Cryoablation At The European Society Of Breast Imaging Annual Scientific Meeting
Featured presentations included 12-month clinical data reporting objective response rates of 97.5% among 40 patients treated with cryoablation plus endocrine therapy and 91.7% among 24 patients treated with cryoablation